TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01952873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged inflation
Description: Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid inflation
Description: The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
Study: NCT04948606

Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.
Study: NCT06010576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided rendezvous
Description: A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early precut papillotomy group
Description: The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
Study: NCT05296603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-322 Plus Lenvatinib
Description: IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-322 Plus Lenvatinib
Description: IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg
Study: NCT05857150

Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill Test
Description: Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
Study: NCT05296603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-322 Plus Lenvatinib
Description: IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg
Study: NCT05846620

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
Study: NCT05857150

Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill Test
Description: Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).

Intervention type: DIAGNOSTIC_TEST
Intervention: Strength Test
Description: Measure the strength of leg muscles by kicking against a machine with resistance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Strength Test
Description: Measure the strength of leg muscles by kicking against a machine with resistance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-Ray Absorptiometry
Description: Body composition measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-Ray Absorptiometry
Description: Body composition measurement.

Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Obtain a small piece of muscles from the upper part of the legs

Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Obtain a small piece of muscles from the upper part of the legs

Intervention type: PROCEDURE
Intervention: Fat Biopsy
Description: Fat sample taken from abdomen

Intervention type: PROCEDURE
Intervention: Fat Biopsy
Description: Fat sample taken from abdomen

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting Energy Expenditure
Description: Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting Energy Expenditure
Description: Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI on upper leg to look at fat and muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI on upper leg to look at fat and muscle
Study: NCT05778461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-Aspartate
Description: LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
Study: NCT01101412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edetate Calcium Disodium
Description: Given through CVC or PVC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Given through CVC or PVC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Given through CVC or PVC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: Given through CVC or PVC
Study: NCT05457777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview in digital game addiction
Description: Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
Study: NCT06188351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Navigation Atrial Septal Puncture
Description: Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Atrial Septal Puncture
Description: Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
Study: NCT06033131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin ER
Description: Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
Study: NCT06544226

Intervention type: DEVICE
Intervention: UH100
Description: This is a non-interventional pilot study. Given the within-subject and longitudinal design used in this study, traditional intervention settings are not applicable. All participants will receive weekly and tri-point assessments,~* Weekly (twice per week) Assessments: Physical vitals such as BMI, Blood Pressure, Heart Rate~* Weekly (once per week) Assessments: Sit-Up-Squat-Stand Test, Video diary entries, GAD-7, and PHQ-9.~* Tri-point (week 1, 8, 6) assessments: EDE-Q, Patient Acceptance Questionnaire and the Food-specific Stop Signal Task.
Study: NCT06506630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: 300 mg capsule twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: 300 mg capsule twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 300 mg capsule twice a day
Study: NCT04774198

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
Study: NCT05431608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCARH125
Description: MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
Study: NCT04345952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation Mobile App
Description: The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
Study: NCT05083975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy System
Description: Vibrating Device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic
Description: 20% benzocaine gel (Opahl Topical Gel)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000
Description: Local dental anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000
Description: Local dental anesthetic agent
Study: NCT05223504

Intervention type: DEVICE
Intervention: Continuously monitoring
Description: Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
Study: NCT05908279

Intervention type: OTHER
Intervention: Walking test
Description: Walk with and without a metronome

Intervention type: OTHER
Intervention: Walking test
Description: Walk with and without a metronome

Intervention type: OTHER
Intervention: Disease assessement
Description: Disease stage assessed by a doctor
Study: NCT05363735

Intervention type: OTHER
Intervention: Ultrasound Elastography
Description: Patients will be examined by ultrasound elastography.
Study: NCT06479850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KF-STRIDE®
Description: Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
Study: NCT05040282

Intervention type: DEVICE
Group type: OTHER
Intervention: Implanon NXT
Description: women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
Study: NCT05309603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded Walking High
Description: Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
Study: NCT03737617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cuvitru 20 % Injectable Solution
Description: Active
Study: NCT05959174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed mitchigen appliance
Description: the process of appliance construction done by intra-oral scanning of the arch and 3d printing
Study: NCT04844502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Description: Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
Study: NCT04589442

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split thickness skin graft
Description: standard of care graft

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microsurfaced split thickness skin graft
Description: standard of care graft that has been microsurfaced
Study: NCT06364267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 MG
Description: Blinded tamoxifen 10 mg every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane 25 MG
Description: Blinded exemestane 25 mg every other day
Study: NCT05309603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded Walking Mid
Description: Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Walking three miles on a treadmill at a self-selected speed
Study: NCT05487729

Intervention type: OTHER
Intervention: ultrasonography and functional assessment and questionnaire survey
Description: ultrasonography and functional assessment and questionnaire survey
Study: NCT05431608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCARH125
Description: MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCARH125
Description: MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
Study: NCT05959174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: side chair appliance
Description: the impresion will be taken to make a cast to reconstruct the appliance
Study: NCT04892875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
Study: NCT05431608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCARH125
Description: MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCARH109
Description: MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
Study: NCT04892875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
Study: NCT05756166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Alpha-2
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Alpha-2
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study: NCT04567849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message
Description: patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message
Description: patient portal message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: provider
Description: nudging calling the patient's provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-nurse
Description: nudging calling the tele-nurse
Study: NCT03986658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear Asymmetric rTMS System
Description: Linear Asymmetric rTMS System
Study: NCT05376540

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct gallbladder injection of ICG intraoperatively
Description: Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravenous injection 2.5 mg
Description: Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravenous injection and direct gallbladder injection
Description: Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravenous injection 5 mg
Description: Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery